CME Presentations
Clinical Updates in Chronic Graft vs Host Disease
Presentations
Clinical Updates in Chronic Graft vs Host Disease and Applications for Academic and Community Practice
Speakers: Zachariah DeFilipp, MD, Director of BMT Clinical ResearchAndrew Rogers, Assistant Professor of Medicine Duration: 30 minutes
Presented on: February 13, 2024
Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice
Speakers: Zachariah DeFilipp, MD, Director of BMT Clinical ResearchAndrew Rogers, Assistant Professor of Medicine Duration: 45 minutes
Presented on: March 20, 2024
Speakers
.jpg)
Zachariah DeFilipp, MD
Zachariah DeFilipp, MD
Director of BMT Clinical Research
Zachariah DeFilipp, MD, is an attending physician in the Hematopoietic Cell Transplant and Cell Therapy Program at the Massachusetts General Hospital Cancer Center. He serves as Director of BMT Clinical Research and an Assistant Professor in Medicine at Harvard Medical School. Dr. DeFilipp is involved in translational and clinical research initiatives to improve outcomes for patients undergoing allogeneic hematopoietic cell transplantation. His research is on the development of approaches to the prevention and treatment of graft-versus-host disease. Also, his research efforts have explored improving transplant outcomes for high-risk leukemia through the incorporation of targeted agents in pre- and post-transplant and examining late effects following amongst long-term transplant survivors.
Andrew Rogers
Andrew Rogers
Assistant Professor of Medicine
Andrew Rogers, MD is a hematologist at MaineHealth Cancer Care in South Portland, Maine. He serves as assistant program director for the Hematology/Medical Oncology Fellowship program at Maine Medical Center. He completed his fellowship training in hematology and medical oncology at The Ohio State University in Columbus, Ohio. His clinical interests include blood cancers such as leukemia, lymphoma, and myeloma.
CME Information
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE).Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Incyte Corporation.DATE OF RELEASE/EXPIRATION
This activity was released on March 20, 2024, and is valid until September 20, 2024. Requests for credit must be made no later than September 20, 2024.TARGET AUDIENCE
The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists.STATEMENT OF NEED/PROGRAM OVERVIEW
Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about recent clinical updates so they can incorporate them into cGvHD management and better anticipate their patients’ needs. Join a panel of hematology/oncology experts, Dr. Zachariah DeFilipp and Dr. Andrew Rogers, to review newly released safety and efficacy data from the recent TANDEM 2024 meeting. Panelists will explore data on existing and emerging therapeutic approaches to manage cGvHD, while discussing the application of these data in both academic and community practice settings.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Review recent evidence for the safety and efficacy of existing and emerging therapies to manage chronic GvHD
- Discuss the applicability of clinical updates in chronic GvHD to the academic and community settings
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 45 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.Faculty Conflicts of Interest Zachariah DeFilipp, MD Director of BMT Clinical Research Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School Researcher: Incyte, Corp., Taiho Oncology, Inc, Regimmune, Corp. Consultant, Advisor, Speaker: Incyte Corp., Sanofi, MorphoSys AG, Inhibrx, PharmaBiome AG, Ono Pharmaceutical Andrew Rogers, MD, MS Assistant Professor of Medicine Tufts University School of Medicine Maine Medical Center Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC (PQHE).Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Incyte Corporation.DATE OF RELEASE/EXPIRATION
This activity was released on February 13, 2024, and is valid until August 13, 2024. Requests for credit must be made no later than August 13, 2024.TARGET AUDIENCE
The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists.STATEMENT OF NEED/PROGRAM OVERVIEW
Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about recent clinical updates so they can incorporate them into cGvHD management and better anticipate their patients’ needs. Join a panel of hematology/oncology experts, Dr. Zachariah DeFilipp and Dr. Andrew Rogers, to review newly released safety and efficacy data from the recent American Society of Hematology (ASH) 2023 meeting. Panelists will explore data on existing and emerging therapeutic approaches to manage cGvHD, while discussing the application of these data in both academic and community practice settings.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Review recent evidence for the safety and efficacy of existing and emerging therapies to manage chronic GvHD
- Discuss the applicability of clinical updates in chronic GvHD to the academic and community settings
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.Faculty Conflicts of Interest Zachariah DeFilipp, MD Director of BMT Clinical Research Assistant Professor of Medicine Massachusetts General Hospital Harvard Medical School Researcher: Incyte, Corp., Taiho Oncology, Inc, Regimmune, Corp. Consultant, Advisor, Speaker: Incyte Corp., Sanofi, MorphoSys AG, Inhibrx, PharmaBiome AG, Ono Pharmaceutical Andrew Rogers, MD, MS Assistant Professor of Medicine Tufts University School of Medicine Maine Medical Center Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
.jpg)
